Medtronic plays catch-up in diabetes
The long-awaited US approval of its newest artificial pancreas comes through, but Medtronic remains behind.
Spotlight – J&J takes on Medtronic and Boston in pulsed field ablation
The group is fast developing its new atrial fibrillation devices. But will it be fast enough?
Medtech approvals stagnate
Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.
Few big bangs in a quiet year for medtech mergers
J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.
Big medtechs’ efficiency starts to recover from Covid
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
Medtech bleeds corporate venture cash
Overall venture investment in the sector remains steady, but the big strategics back off.
TCT 2022 – Edwards tries to Clasp an opportunity
The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?